Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.70 |
| ▸ | ACHE | P22303 | 6/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30105291 | 0.97 | BCHE (0.75) | BCHEACHE | |
| Bromide SCHEMBL7919286 | 0.97 | BCHE (0.71) | BCHEACHE | |
| SCHEMBL7046057 | 0.97 | BCHE (0.75) | BCHEACHE | |
| SCHEMBL7045560 | 0.97 | BCHE (0.75) | BCHEACHE | |
| SCHEMBL2407838 | 0.97 | BCHE (0.75) | BCHEACHE | |
| Ammonia Solution, Strong SCHEMBL28709118 | 0.95 | BCHE (0.71) | BCHEACHE | |
| Bromide SCHEMBL7927268 | 0.95 | BCHE (0.76) | BCHEACHE | |
| Bromide SCHEMBL7927418 | 0.95 | BCHE (0.76) | BCHEACHE | |
| Bromide SCHEMBL2401340 | 0.95 | BCHE (0.76) | BCHEACHE | |
| SCHEMBL31232300 | 0.92 | BCHE (0.65) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297792-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-20 | — | — | US | claimed |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | GARLAND STEPHEN | 2006-10-05 | — | — | US | claimed |
| US-7109199-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | claimed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | claimed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | claimed |
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | SPONDULI SERVICES, LTD. (AU) | 2003-04-03 | — | — | US | claimed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | claimed |
| US-4753908-A | WATER SOLUBLE MACROMOLECULAR ADDITION POLYMERS MIXED WITH SILICA, WATER, AND SMECTITE TYPE MINERALS; FIRING | AGENCY OF INDUSTRIAL SCIENCE (JP) | 1988-06-28 | — | — | US | claimed |
| US-7297792-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | GARLAND STEPHEN | 2006-10-05 | — | — | US | disclosed |
| US-7109199-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | disclosed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | disclosed |
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | SPONDULI SERVICES, LTD. (AU) | 2003-04-03 | — | — | US | disclosed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
| US-4753908-A | WATER SOLUBLE MACROMOLECULAR ADDITION POLYMERS MIXED WITH SILICA, WATER, AND SMECTITE TYPE MINERALS; FIRING | AGENCY OF INDUSTRIAL SCIENCE (JP) | 1988-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | ACIN1, DNA2, KPNA1 | BCHE 3931/4885ACHE 3588/4885 |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | ADK, PDXK, GPR119 | BCHE 2066/4885ACHE 354/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | BCHE 2328/4885ACHE 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.